What is Leerink Partnrs’ Estimate for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Wave Life Sciences in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings per share of ($0.28) for the quarter. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.13) EPS and FY2026 earnings at ($1.12) EPS.

Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.34. The firm had revenue of $83.75 million for the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Several other research analysts have also issued reports on WVE. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, March 26th. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Finally, Jefferies Financial Group started coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 price target on the stock. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Wave Life Sciences Trading Down 4.3 %

WVE opened at $8.62 on Monday. Wave Life Sciences has a 12-month low of $4.25 and a 12-month high of $16.74. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -7.77 and a beta of -1.04. The stock has a fifty day simple moving average of $10.73 and a two-hundred day simple moving average of $11.73.

Insider Activity

In related news, Director Christian O. Henry sold 10,500 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the sale, the director now owns 16,115 shares in the company, valued at approximately $157,443.55. This represents a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. The trade was a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is owned by corporate insiders.

Institutional Trading of Wave Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in shares of Wave Life Sciences during the 4th quarter valued at $40,000. Quarry LP purchased a new position in Wave Life Sciences during the fourth quarter valued at $62,000. KBC Group NV bought a new stake in Wave Life Sciences during the fourth quarter valued at about $67,000. Point72 DIFC Ltd purchased a new stake in Wave Life Sciences in the third quarter worth about $98,000. Finally, Summit Investment Advisors Inc. raised its stake in shares of Wave Life Sciences by 31.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after buying an additional 2,308 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.